Scholarlink

Background <p>Chlormethine gel is a promising treatment for early-stage mycosis fungoides (MF) with strong efficacy and manageable side effects. This study evaluates its effectiveness as a second-line treatment in patients unresponsive to prior skin-directed therapies (SDTs) or combined systemic treatments, hypothesising significant therapeutic benefits with manageable adverse reactions.</p> Methods <p>A retrospective observational study was conducted from April 2021 to December 2022, including adult patients with histologically confirmed MF who had not responded to at least one prior SDT. Patients received daily chlormethine gel applications, and responses were evaluated at 3, 6, and 12&#xa0;months using the Modified Severity-Weighted Assessment Tool (mSWAT). Statistical analyses were performed using SPSS ver 26 (IBM), including one-way ANOVA and univariate regression.</p> Results <p>The study included 21 patients (12 males, 9 females; mean age 61&#xa0;years). 81% had early-stage MF, and 19% had advanced-stage disease. Chlormethine gel showed a 90% response rate, with 33.3% achieving complete response (CR) and 57.1% partial response (PR). Adverse reactions were primarily contact or irritative dermatitis, which were manageable and did not significantly affect outcomes. Median mSWAT scores significantly reduced from baseline at 3, 6, and 12&#xa0;months (P = 0.002).</p> Conclusions <p>Chlormethine gel appeared to be efficacious and safe as a second-line treatment for MF, including in advanced stages. Despite limitations like small sample size and retrospective design, these findings highlight its potential in combination therapies and the importance of continued treatment for optimal outcomes. Future research should confirm these results in larger, prospective studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chlormethine gel effectiveness as second-line treatment in mycosis fungoides: a single-centre retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Corrado Zengarini,
  • Alba Guglielmo,
  • Ludovica Vocale,
  • Andrea Filippini,
  • Federico Bardazzi,
  • Erika Morsia,
  • Iria Neri,
  • Martina Mussi,
  • Bianca Maria Piraccini,
  • Alessandro Pileri

摘要

Background

Chlormethine gel is a promising treatment for early-stage mycosis fungoides (MF) with strong efficacy and manageable side effects. This study evaluates its effectiveness as a second-line treatment in patients unresponsive to prior skin-directed therapies (SDTs) or combined systemic treatments, hypothesising significant therapeutic benefits with manageable adverse reactions.

Methods

A retrospective observational study was conducted from April 2021 to December 2022, including adult patients with histologically confirmed MF who had not responded to at least one prior SDT. Patients received daily chlormethine gel applications, and responses were evaluated at 3, 6, and 12 months using the Modified Severity-Weighted Assessment Tool (mSWAT). Statistical analyses were performed using SPSS ver 26 (IBM), including one-way ANOVA and univariate regression.

Results

The study included 21 patients (12 males, 9 females; mean age 61 years). 81% had early-stage MF, and 19% had advanced-stage disease. Chlormethine gel showed a 90% response rate, with 33.3% achieving complete response (CR) and 57.1% partial response (PR). Adverse reactions were primarily contact or irritative dermatitis, which were manageable and did not significantly affect outcomes. Median mSWAT scores significantly reduced from baseline at 3, 6, and 12 months (P = 0.002).

Conclusions

Chlormethine gel appeared to be efficacious and safe as a second-line treatment for MF, including in advanced stages. Despite limitations like small sample size and retrospective design, these findings highlight its potential in combination therapies and the importance of continued treatment for optimal outcomes. Future research should confirm these results in larger, prospective studies.